ALSO NOTED: J&J reports big revenue growth; Drugmakers fight U.K.'s Aricept ruling;

> Johnson & Johnson reported a 7.7 percent increase in first-quarter sales, to a record-setting $16.2 billion; EPS grew by 8.6 percent to $1.26 excluding special charges. Report

> Eisai, Pfizer, and Shire are fighting a U.K. ruling that restricts access to Alzheimer's drugs such as Aricept to patients in later stages of the disease. Report

> Schering-Plough will report its first-quarter results tomorrow with a conference call; CEO Fred Hassan will offer an update on the company's business and its "major initiatives," most likely including Schering's new $1.5 billion cost-cutting plan. Report

> Abbott Laboratories is prepping for an antitrust trial over the AIDS drug Norvir, scheduled to start Friday. Report

> A combo of Lipitor and Celebrex--both made by Pfizer--inhibited the growth of prostate cancer cells in mice; human trials are being planned. Report | Report

> Genentech and its partner Biogen Idec said their blockbuster lymphoma and rheumatoid arthritis med Rituxan didn't show efficacy against multiple sclerosis in a 96-week trial. Report

> Forest Labs reported fourth-quarter earnings of $172.8 million on a 12 percent increase in revenues to $990.9 million. Release

> Laureate Pharma said it's made a deal with Alopexx Pharmaceuticals to manufacture the latter's product candidate mAb F598 antibody for use in clinical trials. Release

> Teva Pharmaceuticals got 180-day exclusivity for a generic version of the Ortho-McNeil antipsychotic med Risperdal. Report

> Roche said it would pay $160 million for the British pharma Piramed, which is developing meds for cancer and inflammatory diseases such as rheumatoid arthritis. Release

> The European commission gave Bristol-Myers Squibb and Otsuka permission to market their Abilify drug for treatment and prevention of mania in bipolar patients. Report

> Belgian healthcare group Omega Pharma will distribute Chrisal International's anti-dust mite spray in Europe, a Belgian newspaper reports. Report

> Hit by a clinical trial delay triggered by a surprise change-up at the FDA, Canada's Vasogen has hit the brakes on spending and announced plans to lay off 85 percent of its work force. Report

> Shares of AtheroGenics shot up this morning on the news that an interim analysis of late-stage data for AGI-1067 showed a statistically significant reduction in Hemoglobin A1c--a standard measure for blood sugar control. Report

And Finally... New York still feels the effects of a cholera epidemic almost 200 years ago. Report

Suggested Articles

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?

Krystal Biotech has started on a new manufacturing facility for eventual commercial supply of gene therapies in its pipeline.

Chinese authorities have recommended trying AbbVie's HIV combo therapy Kaletra to treat the new coronavirus ravaging the country—and spreading fast.